Advances in Renal Cancer Journalists’ Award: closing date for applications is February 28, 2009
Association of German Medical Journalists and Bayer HealthCare honor outstanding reporting on renal cancer
Leverkusen – Bayer HealthCare and the Association of German Medical Journalists (VDMJ) have jointly announced the 2009 Advances in Renal Cancer Journalists’ Award Europe, which will honor journalists who have dealt with the issue of renal cancer in a critical and objective manner. The award, endowed with €7,500, is donated by Bayer HealthCare. Eligible for the award are printed media, radio, television and film reports.
Journalists may submit their applications by February 28, 2009 to the business address of the Association of German Medical Journalists (Verband Deutscher Medizin Journalisten), Chemnitzer Str. 21, D-70597 Stuttgart. Its statutes can be viewed at www.journalistenvereinigung.de. This information is also available in PDF format in the download area of Bayer HealthCare’s Internet website at www.viva.vita.bayerhealthcare.com
The relevant stories must have been published between March 1, 2008 and February 28, 2009. A jury will decide which journalistic report has best covered the topic of renal cancer in Europe.
The jury comprises four representatives from journalistic organizations and Professor Peter Mulders, Department of Urology, University Medical Center St. Radboud, Nijmwegen (the Netherlands), Dr. Bernard Escudier, Institut Gustave Roussy, Villejuif (France) and one non-voting representive from the sponsor. The award will be presented May 8, 2009 in Berlin at the EU-KCO Symposium (Fourth European International Kidney Cancer Symposium – www.kidneycancersymposium.com).
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at www.bayerhealthcare.com.
Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company. Its research and business activities are focused on the following areas: Diagnostic Imaging, General Medicine, Specialty Medicine and Women’s Healthcare. Bayer Schering Pharma is committed to innovation and aims to be a global leader with novel products in specialized markets. In this way Bayer Schering Pharma contributes to medical progress with the aim of improving people’s quality of life. More information is available at www.bayerscheringpharma.de
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.